Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ... [Yahoo! Finance]
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: Yahoo! Finance
Service Revenue: Grew 25% versus Q3 of last year. GAAP Gross Profit: $29 million, 56% gross margin. Adjusted Gross Profit Margin: 60% in the quarter. Operating Expenses: $33.3 million, down 2% from Q2. Research and Development Expenses: $9.9 million, down from $11.2 million in the prior year period. Sales and Marketing Expenses: $12.4 million, in line with Q2. General and Administrative Expenses: $10.9 million, down from $11.7 million in Q2. Loss from Operations: $4.2 million, improved from $6.4 million loss in Q3 2023. GAAP Net Income: $0.9 million, compared to a net loss of $6.5 million in the prior year. Adjusted EBITDA: $7.6 million, up from $2.9 million in Q2 and $3.7 million in Q3 2023. Total Cash and Marketable Securities: $277.8 million. Share Repurchase: $12.1 million spent to repurchase 2.2 million shares. Full Year Revenue Outlook: $203 million to $210 million, 5% to 9% growth over 2023. Warning! GuruFocus has detected 1 Warning Sign with CTKB.
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramGlobeNewswire
- Cytek Biosciences, Inc. (NASDAQ: CTKB) had its price target raised by analysts at Piper Sandler from $8.00 to $8.50. They now have an "overweight" rating on the stock.MarketBeat
- Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterGlobeNewswire
- Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CTKB
Earnings
- 11/5/24 - Beat
CTKB
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- CTKB's page on the SEC website